File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo

TitleInhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivo
Authors
Issue Date2012
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/07357907.asp
Citation
Cancer Investigation, 2012, v. 30 n. 5, p. 380-389 How to Cite?
AbstractBackground: CD164 (Endolyn) is a sialomucin, which has been found to play roles in regulating proliferation, adhesion, and differentiation of hematopoietic stem cells. Possible association of CD164 with solid cancer development remains unknown. Methods and Results: We first studied CD164 expression in biopsies from colorectal cancer, breast, and ovary cancer patients by semi-quantitative immunohistochemistry, and found that CD164 was strongly expressed in all the colorectal cancer samples compared to the matching normal colon tissues. The possible roles of CD164 in colon cancer development were further investigated using a well-established human colon cancer cell line HCT116. We found that knockdown of CD164 expression in HCT116 cells significantly inhibited cell proliferation, mobility, and metastasis in vitro and in vivo. The knockdown of CD164 expression was associated with decreased chemokine receptor CXCR4 expression HCT116 cell surface and immunoprecipitation studies showed that CD164 formed complexes with CXCR4. Conclusions: CD164 is highly expressed in the colon cancer sites, and it promotes HCT116 colon cancer cell proliferation and metastasis both in vitro and in vivo, and the effects may act through regulating CXCR4 signaling pathway. Therefore, CD164 may be a new target for diagnosis and treatment for colon cancer. Copyright © 2012 Informa Healthcare USA, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/170200
ISSN
2015 Impact Factor: 2.231
2015 SCImago Journal Rankings: 0.991
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, Jen_US
dc.contributor.authorZhang, Len_US
dc.contributor.authorShe, Xen_US
dc.contributor.authorZhou, Gen_US
dc.contributor.authorYu, Fen_US
dc.contributor.authorXiang, Jen_US
dc.contributor.authorLi, Gen_US
dc.date.accessioned2012-10-30T06:06:07Z-
dc.date.available2012-10-30T06:06:07Z-
dc.date.issued2012en_US
dc.identifier.citationCancer Investigation, 2012, v. 30 n. 5, p. 380-389en_US
dc.identifier.issn0735-7907en_US
dc.identifier.urihttp://hdl.handle.net/10722/170200-
dc.description.abstractBackground: CD164 (Endolyn) is a sialomucin, which has been found to play roles in regulating proliferation, adhesion, and differentiation of hematopoietic stem cells. Possible association of CD164 with solid cancer development remains unknown. Methods and Results: We first studied CD164 expression in biopsies from colorectal cancer, breast, and ovary cancer patients by semi-quantitative immunohistochemistry, and found that CD164 was strongly expressed in all the colorectal cancer samples compared to the matching normal colon tissues. The possible roles of CD164 in colon cancer development were further investigated using a well-established human colon cancer cell line HCT116. We found that knockdown of CD164 expression in HCT116 cells significantly inhibited cell proliferation, mobility, and metastasis in vitro and in vivo. The knockdown of CD164 expression was associated with decreased chemokine receptor CXCR4 expression HCT116 cell surface and immunoprecipitation studies showed that CD164 formed complexes with CXCR4. Conclusions: CD164 is highly expressed in the colon cancer sites, and it promotes HCT116 colon cancer cell proliferation and metastasis both in vitro and in vivo, and the effects may act through regulating CXCR4 signaling pathway. Therefore, CD164 may be a new target for diagnosis and treatment for colon cancer. Copyright © 2012 Informa Healthcare USA, Inc.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/07357907.aspen_US
dc.relation.ispartofCancer Investigationen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntigens, Cd164 - Analysis - Physiologyen_US
dc.subject.meshCell Movementen_US
dc.subject.meshCell Proliferationen_US
dc.subject.meshChemokine Cxcl12 - Physiologyen_US
dc.subject.meshColonic Neoplasms - Pathology - Therapyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHct116 Cellsen_US
dc.subject.meshHumansen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Balb Cen_US
dc.subject.meshNeoplasm Metastasisen_US
dc.subject.meshReceptors, Cxcr4 - Physiologyen_US
dc.titleInhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation, mobility, and metastasis in vitro and in vivoen_US
dc.typeArticleen_US
dc.identifier.emailZhou, G:wormoscz@gmail.comen_US
dc.identifier.authorityZhou, G=rp00527en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3109/07357907.2012.666692en_US
dc.identifier.pmid22409183-
dc.identifier.scopuseid_2-s2.0-84861041373en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84861041373&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume30en_US
dc.identifier.issue5en_US
dc.identifier.spage380en_US
dc.identifier.epage389en_US
dc.identifier.isiWOS:000304067800005-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridTang, J=55217597200en_US
dc.identifier.scopusauthoridZhang, L=48663195100en_US
dc.identifier.scopusauthoridShe, X=38663444700en_US
dc.identifier.scopusauthoridZhou, G=23394245100en_US
dc.identifier.scopusauthoridYu, F=8424228100en_US
dc.identifier.scopusauthoridXiang, J=7201546177en_US
dc.identifier.scopusauthoridLi, G=36013406300en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats